Lymphoma & Myeloma Clinical Trials
Last Updated: 10/24/2022
CAR T/Cellular Therapy
Lymphoma CAR T/Cellular Therapy
Previously Untreated
2022-0463 An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma
Previously Treated
2021-0543 Evaluating the Feasibility Of a Digital Health Coaching for Individuals Following CAR T Therapy
2021-0622 Evaluation of Risk of Early Death after CD19 CART Cell Therapy for LBCL
2020-1136 A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
2021-0168 A Phase 1, First-In-Human, Open-Label, Multicenter, Multicohort Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4-CAR-T) in Subjects with Relapsed or Refractory T-Cell Lymphoma (TCL)
2020-1073 (CERTAIN-TESSCAR002): Phase 1 Study of CD30-directed Genetically Modified Autologous T cells (CD30 CAR-T) in Patients with Relapsed or Refractory CD30 Positive Non Hodgkins Lymphoma
2020-1263 Long-term Follow-up Protocol for Subjects Treated with Adicet Bio Allogeneic Gamma Delta T-cell Investigational Products
2020-1137 (CD20): A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta (?d) T Cells in Adults with B Cell Malignancies, in Monotherapy and Combination with IL-2
2020-1172 Use of tocilizumab for the clinical management of by CAR-T cell therapy-induced CRS
2020-0502 An Observational Study to Evaluate A Wearable Temperature Monitoring Device in Subjects Receiving CAR - T Therapy
2020-1041 (ANTLER): A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ANTLER)
2019-1250 A Phase 2, Open-label, ingle-arm, Multi Cohort, Multi Center Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B-Cell Non-Hdgkin Lymphoma (NHL)
2020-0120 Cardiovascular Events Among Adults Patients with Aggressive B-Cell Lymphoma Treated with Standard of Care Chimeric Antigen Receptor T Cell Therapy: A Single-Institution Experience
2019-0925 Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in a Precision BioSciences, Inc., Clinical Study
2019-1051 Pilot study of anakinra to mitigate CAR-T toxicity in subjects with relapsed or refractory large B-cell lymphoma
2018-1134 (LOXO-305): A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin's Lymphoma (NHL)
2017-0730 ( JCAR017): An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM)
2017-0946 Long-Term Follow-Up Protocol For Subjects Treated With Gene-Modified T Cells
2015-0529 (JCAR017): Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
2015-0569 Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CART Cell Therapy
2019-0940 A Multicenter, Open-label, Expanded Access Study of KTE-X19 for the Treatment of Subjects with Relapsed/Refractory B-Cell Malignancies Zuma 18
Myeloma CAR T/Cell Therapy
Previously Treated
2022-0042 Outcomes of CAR T Therapy in Multiple Myeloma
2021-0543 Evaluating the Feasibility Of a Digital Health Coaching for Individuals Following CAR T Therapy
2021-0513 A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy and Cellular inetics /Pharmacodynamics of ALLO-647 and ALLO-605, an Anti-BCMA Allogenic CAR T Cell Therapy in Patients with Relapsed /Refractory Multiple Myeloma
2018-0572 (KarMMa-2): A Phase 2, Multicohort, Open-label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2)
2017-1012 (AMG701): A Phase 1/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 Monotherapy, or in Combination With Pomalidomide, With and Without Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
2017-0494 (UCARTCS1): Phase I, Open Label Dose-Escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of A Single Dose of UCARTCS1 (Allogeneic Engineered T-Cells Expressing Anti-CS1 Chimeric Antigen Receptor), Administered In Patients with Relapse
2017-0444 (P-BCMA-101): Open-Label, Multicenter, Phase 1 Study to Assess theSafety of P-BCMA-101 in Subjects with Relapsed /Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME)
Lymphoma Clinical Trials
Non Hodgkins Lymphoma
Indolent Lymphoma (Follicular, Marginal Zone, Small Lymphocytic Leukemia)
Newly Diagnosed
2021-0260 Retrospective analysis of survival outcomes for patients with previously untreated follicular lymphoma
2017-0859 ILyAD Vit D vs placebo with Rituxan monotherapy for untreated iNHL (SLL, FL, MZL)
2011-0283 Randomized Trial of Radiation Therapy with and without Rituximab for patients with Stage I II Follicular Lymphoma grade I/II/IIIa
Previously Treated
2022-0394 A Phase lb, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, And Efficacy OfMosunetuzumab Or Glofitamab In Combination With CC-220 And CC-99282 In Patients With B-Cell Non-Hodgkin Lymphoma
2022-0298 A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma
2022-0206 A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, PK/PD, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients With Relapsed or Refractory B-cell NHL
2019-1075 Characterization of BCL2 Alternative Proteins and theTumor Microenvironment in Patients with Follicular Lymphoma
2021-0499 Phase III, Randomized, Open-label, multicenter studyevaluating efficacy and safety of mosunetuzumab incombination with lenalidomide in comparison torituximab in combination with lenalidomide in patients with follicular lymphoma after at least one line of systemic therapy (Celestimo)
2021-1003 A Phase 1, Open-Label, Dose-Escalation and-Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
PA13-0251 Long-term outcomes in patients with Folliuclar Lymphoma at MD Anderson in the Rituximab Era
2021-0647 An Open-Label, Multicenter, Phase 2 Study of CLR131 in Patients with Relapsed or Refractory (R/R)Select B-Cell Malignancies (CLOVER-1) andExpansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)
2021-0440 A Collection of Blood and Tissue Samples fromPatients with Amyloidosis and/or MonoclonalGammopathies (including Lymphoplasmacytic Lymphoma) and Normal Donors
2021-0583 A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
2021-0454 A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination with Ublituximab in Subjects with B-Cell Lymphoma or Chronic Lymphocytic Leukemia
2021-0111 A Phase 1, Multicenter, Open-Label, Dose Finding Study of CC-96673 in Subjects with Relapsed or Refractory Non-Hodgkin's Lymphoma
2021-0226 A Phase I/II Open Label, Single Center, Study of the Combination of ALX148, Rituximab and Lenalidomide in Patients with Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
2021-0091 A Multicenter, Phase1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-cell Non Hodkins Lymphoma
2021-0109 A Phase 3, Randomized, Dounle-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab versus Lenalidomide in Addition to Rituximab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma
2021-0166 An Open-label, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Vedotin in Patients with B-cell Non-Hodgkin Lymphoma
2020-0693 A Three-arm Study of ME-401 Monotherapy in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL), of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL
2020-0272 A phase 1B/3 double-blind, randomized, active-contrlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractor follicular lymphoma
2020-0177 (SWOGS1608): Randomized Phase II Trial In Early Relapsing Or Refractory Follicular Lymphoma
2020-0293 (GEN3009): Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma “A First-in-Human, Open-label, Phase I/IIa Dose Escalation Trial with Dose Expansion Cohorts
2020-0452 A Phase 1, First-in-human, Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants with NHL and CLL
2020-1029 A Phase 1B Trial of Nivolumab Consolidation Following Completion of High-Dose Methotrexate Containing Induction Chemotherapy in Older (= 65) Patients with Primary CNS Lymphoma
2020-0639 (AZD4573) : A Modular Phase I/II, Open-label, Multicentre Study to AssessAZD4573 in Novel Combinations with Anti-cancer Agents in Patients with Advanced Haematological Malignancies
2020-0034 (aR2): A Phase II Study of Acalabrutinib, Lenalidomide and Rituximab (aR2) in Patients with Previously Untreated High Tumor Burden Follicular Lymphoma
2019-0644 (IGM-2323): Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas
2019-0313 (CG-806): A Phase 1 a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin's Lymphomas
2019-0123 (HMPL-523): A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma
2019-0615 (FT516): A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma
2019-0956 (CC-95251) : A Phase 1, Open-Label, Dose Finding Study of CC-95251, a Monoclonal Antibody Directed against SIRPa, Alone and in Combination with Cetuximab or Rituximab in Subjects with Advanced Solid and Hematologic Cancers
2019-1132 (FT596): A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination with Rituximab or Obinutuzumab in Subjects with Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia
2018-1160 (CC-99282): A Phase I, Multi-Center, Open Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkins Lymphoma
2018-0996 (VLS-101): A Phase 1 dose-escalation and cohort-expansion study of VLS-101 in subjects with Hematological Malignancies
2017-0141 (BTCT4465): An Open-label, Multicenter, Phase I/Ib Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined with Atezolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma And Chronic Lymphocytic Leukemia
2017-0475 (UC-961): A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies
2017-0224 (Ibrutinib): Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Aggressive Lymphoma (Large B cell Lymphoma, Diffuse Large B cell Lymphoma, Burkitt's Lymphoma)
Newly diagnosed
2021-0046 Smart Stop: A Phase II trial of Rituximab,Lenalidomide, Acalabrutinib, Tafasitamab prior to andwith standard chemotherapy for patients with newly diagnosed DLBCL
2021-0370 A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL)
2021-0369 A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated, Poor Risk (IPI 3 to 5), Aggressive B-cell Lymphoma
2020-0686 A Phase II Study to Determine the Response Kinetics, Safety and Efficacy of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-cell Lymphoma
Previously Treated
2022-0358 Real-World Outcomes in Patients with Relapsed or Refractory (R/R) Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)
2022-0405 A Phase 2 Study ofMivavotinib in BiomarkerDefined Subgroups of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
2022-0147 A Phase II Study ofLoncastuximab Tesirine as Consolidation Strategy in Patients with Large B-cell Lymphoma who Achieve Partial Remission After CAR T-cell Therapy
2022-0342 A Phase 2 Open-label Study ofLoncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)
2022-0316 A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study ofZilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
PA15-0957 DNA Sequencing-Based Monitoring of MinimalResidual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
PA13-0046 A Retrospective Evaluation of Patients Treated at MDAnderson Cancer Center for Relapsed Diffuse Large B-cell Lymphoma
2021-0647 An Open-Label, Multicenter, Phase 2 Study of CLR131 in Patients with Relapsed or Refractory (R/R)Select B-Cell Malignancies (CLOVER-1) andExpansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)
2021-0211 Outcomes of Extensive Stage Plasmablastic Lymphoma
2020-0184 A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
2018-1049 A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic CAR T Cell Therapy In Patients With Relapsed/Refractory Large B-Cell and Follicular Lymphoma
2021-0181 A Multicenter Phase 2 Study of Belantamab mafodotin in Relapsed or Refractory Plasmablastic Lymphoma and ALK+ Large B-cell Lymphoma
2021-0463 An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
2021-0467 An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) in subjects with advanced cancer
2021-0263 A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
2019-0605 (CPI-613): A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or high-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6
2019-0644 (IGM-2323): Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas
2018-1160 (CC-99282): A Phase I, Multi-Center, Open Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkins Lymphoma
2018-0996 (VLS-101): A Phase 1 dose-escalation and cohort-expansion study of VLS-101 in subjects with Hematological Malignancies
2018-0510 (NIVO): Nivolumab and Ibrutinib for Relapsed or Refractory Central Nervous System Lymphoma
2017-0141 (BTCT4465): An Open-Label, Multicenter, Phase I/II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Escalating Doses of Mosunetuzumab (BTCT4465A) as a Single Agent and Combined With Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
2014-0539 (ACP-196): Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) In Subjects with Relapsed Follicular Lymphoma
2021-0915 A Phase 1/1b, Open-label Multi-center Two-part Study of SETD2 Inhibitor EZM0414 in Subjects with Relapsed/refractory Multiple Myeloma and Relapsed/refractory Diffuse Large B Cell Lymphoma
Mantle Cell Lymphoma
Previously Treated
PA17-0227 A Study To Evaluate The Efficacy And Toxicity OfVenetoclax In Patients With Relapsed/RefractoryMantle Cell Lymphoma Treated At MD Anderson Cancer Center
2021-0647 An Open-Label, Multicenter, Phase 2 Study of CLR131 in Patients with Relapsed or Refractory (R/R)Select B-Cell Malignancies (CLOVER-1) andExpansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)
2020-1242 A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor inPatients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
2013-0090 A Phase II Study of Ibrutinib Plus Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma
2021-0339 A Modular Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)
2020-0638 (BGB-3111): An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) in Patients with B cell malignancies
2020-0858 (Acal-Rit): A Phase II Study of Acalabrutinib plus rituximab in previously untreated elderly patients with Mantle Cell Lymphoma
2019-0123 (HMPL-523): A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma
2019-0421 (ACAL): A Phase II Study of Acalabrutinib in Ibrutinib-Intolerant Mantle Cell Lymphoma
2019-0469 (BGB-3111): A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
2019-0922 (ICP-022): A Phase I, Multicenter, Open-Label, Dose EscalationStudy of a Novel BrutonÂfs Tyrosine Kinase Inhibitor, ICP-022, in Patients with Relapsed/Refractory B-Cell
2019-1022 (Match): A Pilot Study of Interrogating biological Signaling Pathways Dysregulations and in vitro Screening with Personalized Therapies in resistant Mantle Cell Lymphoma (MCL) - the MCL Match Trial
2018-0996 (VLS-101): A Phase 1 dose-escalation and cohort-expansion study of VLS-101 in subjects with Hematological Malignancies
2018-0935 (Venetoclax & Acalabrutinib): An open label, Phase II investigator initiated study of venetoclax and acalabrutinib in previously treated relapsed/refractory patients with mantle cell lymphoma (MCL)
2017-0475 (UC-961): A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies
2017-0051 (PDX): A Pilot Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response: The EXPLORE trial
2017-0238 Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma
2016-0914 (Ib-Smol): A Phase II Trial of Ibrutinib in previously untreated high risk smoldering mantle cell lymphoma (MCL)
2015-0372 A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)
2018-1090 A Phase 2 Study of Ixazomib and Rituximab in Bruton Tyrosine Kinase Inhibitor Resistant Mantle Cell Lymphoma
2018-0348 Phase II Trial to assess the Efficacy of Ultra Low Radiation Dose delivered prior or after chemotherapy free targeted therapy for the Treatment of R/R MCL
Hodgkin Lymphoma
Newly Diagnosed
2020-0460 (CD30.CAR-T): A Phase 2 Multi-Center Study Evaluating the Safety and Efficacy of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) in Adult and Pediatric Patients with Relapsed or Refractory CD30 Positive Classical Hodgkin Lymphoma
2019-1153 (SWOGS1826): A phase III, randomized study of nivolumab (OPDIVO) plus AVD or BRENTUXIMAB VEDOTIN (ADCETRIS) plus AVD in patients (AGE >/= 12 YEARS) with newly diagnosed advanced stage classical hodgkins lymphoma.
2018-1061: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Previously Treated
2022-0347 Phase 1b Study Evaluating the Safety and Efficacy of Autologous CD30.CAR-T in Combination With PD-1 Checkpoint Inhibitor (Nivolumab) in Relapsed or Refractory Classical Hodgkin Lymphoma Patients After Failure of Frontline Therapy (ACTION)
2020-0884 Retrospective analysis of stool microbiome in patients treated with immunomodulatory agents in the frontline and relapsed classical Hodgkin Lymphoma
2021-0963 A Modular Phase II, Open-label, Multicentre Study toAssess AZD4573 Efficacy and Safety as Monotherapyor in Combination with Anti-cancer Agents in Patientswith Relapsed/Refractory Peripheral T-cell Lymphoma or classical Hodgkin Lymphoma
2021-0731 Multicenter Retrospective Studies about FrontlineTherapies of Classical Hodgkin Lymphoma Including Brentuximab Vedotin and chemotherapy
2020-0085 (PTCL): A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
2019-0123 (HMPL-523): A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma
2019-0981 (CD30 - PTCL): A Phase 2, Multicenter, Single-Arm Study of Retreatment with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-Expressing Peripheral T Cell Lymphoma (PTCL)
2019-0318 (cHL): A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
2018-0114 (DVD-AVD): A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
2017-0731 (PD-1 + ICE): A phase II trial of response-adapted second-line therapy for Hodgkin lymphoma using anti-PD-1 antibody nivolumab +/- ICE chemotherapy as a bridge to autologous hematopoietic cell transplant (NICE Trial)
2019-1078 A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma
T-Cell Lymphoma
Newly Diagnosed
2022-0112 An Open label, Phase II Study to Evaluate the Efficacy and Safety ofTenalisib (RP6530), given with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) therapy for front line treatment in Patients with Peripheral T-cell Lymphoma
2021-0058 A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects with Peripheral T-cell Lymphoma (PTCL) with less than 10% CD30 Expression
2021-0148 A Multi-center Phase Ib Trial Evaluating the Safety and Efficacy of Lacutamab in Patients with Relapsed Peripheral T-cell Lymphoma that Express KIR3DL2
2017-0927 A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas
Previously Treated
2022-0235 A Single-arm, Phase II Study to Evaluate the Efficacy and Safety ofLinperlisib (YY-20394) Monotherapy in Patients with Relapsed or Refractory Peripheral T/NK. Cell Lymphoma
2021-0388 A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-toumor Activity AZD4205 in Patients with Peripheral T Cell Lymphoma (PTCL)
2019-0755 (REDIRECT): A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)
2018-1064 (TTI-622): A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advance Relapsed or Refractory Lymphoma or Myeloma
2017-0272 (MK-3475): A Phase I/II Study of Pembrolizumab (MK-3475) in Combination with Romidepsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
2021-1033 An open-label, multi-center, non-randomized phase I dose escalation study to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory T-cell Lymphoma
2021-0971 An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
Multiple Myeloma Clinical Trials
Newly Diagnosed
2021-0442 Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide,and Dexamethasone vs Carfilzomib, Lenalidomide,and Dexamethasone vs Bortezomib, Lenalidomide,and Dexamethasone in Patients with Newly-Diagnosed Multiple Myeloma (ADVANCE)
2021-0191 (DETER-SMM) EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
2020-0472 (CAEL-101 Amy): A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naive Patients with Mayo Stage IIIa AL Amy
2019-0556 (TAK-079): An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy
2019-0304 (NDMM): A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
2018-0345 (Vaccine in SMM): A Personalized Vaccine for the Immune Prevention of Multiple Myeloma
Previously Treated
2020-1229 A Phase 3 randomized, open label, multicenter study ofisatuximab (SAR650984) in combination withlenalidomide and dexamethasone versus lenalidomideand dexamethasone in patients with high-risk smoldering multiple myeloma
2017-0618 A Phase 1/2 Multicenter, Open-Labelstudy To Assess The Safety,Pharmacokinetics And Efficacy Of Cc-92480 Monotherapy And In Combinationwith Dexamethasone In Subjects Withrelapsed And Refractory Multiple Myeloma
2020-0973 Expanded Access Protocol (EAP) for Subjectsreceiving Idecabtagene Vicleucel that is Nonconforming for Commercial release
2021-1104 Outcomes in multiple myeloma patients treated with belantamab mafodotin
2016-0172 Quality of Life in Patients with Asymptomatic Monoclonal Gammopathies
2011-0872 Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients with Relapsed and Refractory Disease
2021-0647 An Open-Label, Multicenter, Phase 2 Study of CLR131 in Patients with Relapsed or Refractory (R/R)Select B-Cell Malignancies (CLOVER-1) andExpansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)
20 21-0185 A Phase 1/2a, First-in-human Study to Evaluate theSafety, Tolerability, Pharmacokinetics, and Efficacy ofHDP-101 in Patients with Plasma Cell Disorders Including Multiple Myeloma
2021-0309 Clinical and Patient Reported Outcomes for Individualswith Relapsed/Refractory Multiple Myeloma Treatedwith Isatuximab: Real-World Insights from PatientReported, Wearable, and Qualitative Data in the Context of a Digital Health Coaching Program
2020-0934 An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of BB2121 (IDE-CEL) Combinations in Subjects with Relapsed/Refractory Multiple Myeloma
2020-1124 Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody)nin Patients with Relapsed or Refractory Multiple Myeloma
2020-0464 (CAEL-101): Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amylo
2020-0720 A Non-Interventional, Multinational, Observational Study with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
2020-0146 (PBCAR269A):A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion Study to Evaluate the Safety and Clinical Activity of PBCAR269A, with or without nirogacestat, in Study Subjects with Relapsed/Refractory Multiple Myeloma
2020-0113 (MYD88):A Phase 1b Trial of Mavorixafor, an Oral CXCR4 Antagonist, in Combination With Ibrutinib in Patients With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
2020-0534 (APG-2575):A Phase Ib /II Study of Safety, Tolerability and Efficacy of APG-2575 Alone or in Combination with Other Therapeutic Agents in Patients with Waldenstrom Macroglobulinemia (WM)
2020-0103 (BFCR4350A):An Open-Label, Multicenter, Phase I Trial Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of BFCR4350A In Patients With Relapsed Or Refractory Multiple Myeloma
2020-0610 (ION-251): A Phase 1 Study of ION251 Administered by Intravenous Infusion to Patients with Relapsed/Refractory Multiple Myeloma
2019-0452 (RRMM): A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)
2019-0499 (CT053): Open label, multi-center, phase 1b clinical trial to evaluate the safety and efficacy of autologous CAR-BCMA T cells (CT053) in patients with relapsed and/or refractory multiple myeloma
2019-0624 (NKTR-255): A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 in Relapsed or Refractory Hematological Malignancies
2019-1090 (NDMM): A Phase I, Open-label, Multicenter Study to Evaluate the Safety of BB2121 in Subjects with High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
2018-0710 (P-BCMA-101): Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated with P-BCMA-101
2018-0512 (D+B-Dex in R/R MM): A Phase 2 Study of Daratumumab, Bortezomab and Dexamethasone followed by Daratumumab, Ixaazomib, and Dexamethasone for Relapsed/Refractory Myeloma
2018-0285 (Ventelocla): A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11 14)-Positive Relapsed or Refractory Multiple Myeloma
2018-0192 (XmAb13676): A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 in Patients with CD20-Expressing Hematologic Malignancies
2017-0243 (AL AMY): A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
2015-0148 Phase II Trial Of Isatuximab With or Without Lenalidomide In Patients With High Risk Smoldering Multiple Myeloma
2021-0915 A Phase 1/1b, Open-label Multi-center Two-part Study of SETD2 Inhibitor EZM0414 in Subjects with Relapsed/refractory Multiple Myeloma and Relapsed/refractory Diffuse Large B Cell Lymphoma
Other Clinical Trials
2022-0381 Clinical and Genomic Factors for Prognosis of Primary Effusion Lymphoma
2022-0193 Outcomes of Cutaneous T-Cell Lymphoma Patients on Mogamulizumab
2022-0052 A Prospective Study Of Conventional Bone Marrow Biopsies And Bone Marrow Biopsies Performed Through An Indwelling Bone Marrow
022-0417 SMOLDERING MYELOMA REGISTRATION TRIAL (SMRT STUDY)
2022-0396 Feasibility of Combined Genomics/Transcriptomics for Patients with Lymphoma
2022-0167 Precision Approaches to Treat Mantle Cell Lymphoma: Integrating Multi-omics Based Models
2022-0437 A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy ofDR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
2022-0333 Data Collection for Patients Transitioned to Survivorship Clinics
2022-0211 Clinical and Genomic Prognostic Factors in Plasmablastic Lymphoma (PBL)
2021-0473 Clinical and molecular characteristics of patients withmultiple primary hematological neoplasms in patients with lymphoma
2021-0392 Collection of blood samples from normal donors
2021-0371 Safety, efficacy and outcomes of CAR-T therapy inpatients with post-transplant lymphoproliferative disorder (PTLD)
2021-0841 Epidemiology of Lymphomas in Latin America
2021-0402 Clinical and molecular characteristics of splenic lymphoma
2021-0470 Patient Characteristics and Outcomes in Relapsed Lymphoma in Pregnancy
2005-0656 A Collection of Blood and Tissue Samples fromPatients with Lymphoma and/or Myeloma and Normal Donors
2021-0816 A Study to Evaluate Long-Term Safety of CAR-T Cell Therapy in Patients with Hematologic Malignancies
2021-0696 A Phase 2, Open-label Study to Evaluate the Safety andEfficacy of MK-7684A (MK-7684 [Vibostolimab] withMK-3475 [Pembrolizumab] Coformulation) inParticipants with Relapsed or Refractory Hematological Malignancies2021
2021-0239 A Novel Model To Predict Transplant-related Mortality In Light Chain Amyloidosis: A Collaborative Study
2021-0120 Assessing the effectiveness of CNS prophylaxisstrategies in patients with diffuse large B-celllymphoma and CNS-IPI 4 and high-grade B-cell lymphoma: a multi-center, retrospective analysis
2021-0438 Primary gastric aggressive non-Hodgkin lymphoma: an international, multi-centre retrospective study
2021-0847 Retrospective analysis of phase 1 trials in lymphoma
2020-0892 Predictive Factors for Outcomes of Patients withToxoplasma Infection Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
2020-0228 IRB PA 2020-0228 Clinical, Biological, Radiologicaland Outcome Characterizations of Primary Mediastinal B Cell Lymphoma
2022-0145 Mortality Patterns Among Cancer Survivors Receiving Care in Dedicated Survivorship Clinics
2020-1134 Cord blood source for cellular therapy
2013-0367 Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Patients with Stage I/II Nasal NK Cell lymphoma
2014-1046 Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma
2020-0238 A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Adult Subjects With R/R T or B Cell Malignancies
2021-0971 An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)